{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:41:33Z","timestamp":1787636493747,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001736","name":"German-Israeli Foundation for Scientific Research and Development","doi-asserted-by":"publisher","award":["GIF I-1417-201.2\/2017"],"award-info":[{"award-number":["GIF I-1417-201.2\/2017"]}],"id":[{"id":"10.13039\/501100001736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001736","name":"German-Israeli Foundation for Scientific Research and Development","doi-asserted-by":"publisher","award":["GIF I-1417-201.2\/2017"],"award-info":[{"award-number":["GIF I-1417-201.2\/2017"]}],"id":[{"id":"10.13039\/501100001736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Histochem Cell Biol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several risk factors like obesity and hyperlipidemia were described for endometrial cancer. Here, the nuclear NAD-dependent histone-deacetylase Sirtuin1 (SIRT1) seems to be important. SIRT1 is also involved in cell regulatory mechanisms and can serve as tumor promotor or suppressor. Its role in tumor biology is not clear yet. In this study, we evaluated and correlated the SIRT1 expression with patients\u2019 tumor characteristics in endometrioid and clear-cell cancer of the uterus. 65 paraffin-embedded samples of patients with endometrial and clear-cell cancer of the uterus were immunohistochemically stained and SIRT1 expression was evaluated by immunoreactive score. The results were correlated to clinical and pathological tumor characteristics as well as to the expression of ARID1A and \u03b2-Catenin. The staining was significantly more intensive in uterine endometrioid carcinoma compared to uterine clear-cell carcinoma (<jats:italic>p<\/jats:italic>\u2009=\u20090.007). The expression of SIRT1 correlated significantly with the membranous expression of \u03b2-Catenin (<jats:italic>p<\/jats:italic>\u2009=\u20090.028) and ARID1A (<jats:italic>p<\/jats:italic>\u2009=\u20090.021). Patients with positive Sirtuin1 expression had a significantly better progression-free survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.042), the overall survival showed a trend towards a better prognosis (<jats:italic>p<\/jats:italic>\u2009=\u20090.070). SIRT1 expression seems to be associated with improved progression-free survival in uterine cancer (endometrioid and clear-cell) and is correlated to the tumor suppressors \u03b2-Catenin and ARID1A. Further studies are necessary to elucidate the role of SIRT1 in uterine and ovarian cancer and its potential as a therapeutic target.<\/jats:p>","DOI":"10.1007\/s00418-020-01873-x","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T03:12:02Z","timestamp":1593486722000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer"],"prefix":"10.1007","volume":"154","author":[{"given":"Susanne","family":"Beyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Czogalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa M.","family":"Kolben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Trillsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Schm\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Mayerhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Jeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kolben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,9]]},"reference":[{"issue":"3","key":"1873_CR1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/IGC.0000000000000075","volume":"24","author":"AT Ali","year":"2014","unstructured":"Ali AT (2014) Reproductive factors and the risk of endometrial Cancer. Int J Gynecol Cancer 24(3):384. https:\/\/doi.org\/10.1097\/IGC.0000000000000075","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"1873_CR2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/labinvest.2015.119","volume":"95","author":"R Asaka","year":"2015","unstructured":"Asaka R, Miyamoto T, Yamada Y, Ando H, Mvunta DH, Kobara H, Shiozawa T (2015) Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: a novel therapeutic target. Lab Invest 95(12):1363\u20131373. https:\/\/doi.org\/10.1038\/labinvest.2015.119","journal-title":"Lab Invest"},{"issue":"4","key":"1873_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2008.08.014","volume":"8","author":"AS Banks","year":"2008","unstructured":"Banks AS, Kon N, Knight C, Matsumoto M, Guti\u00e9rrez-Ju\u00e1rez R, Rossetti L et al (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8(4):333\u2013341. https:\/\/doi.org\/10.1016\/j.cmet.2008.08.014","journal-title":"Cell Metab"},{"issue":"2","key":"1873_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.18632\/oncotarget.6691","volume":"7","author":"C Bartosch","year":"2016","unstructured":"Bartosch C, Monteiro-Reis S, Almeida-Rios D, Vieira R, Castro A, Moutinho M et al (2016) Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium. Oncotarget 7(2):1144\u20131154. https:\/\/doi.org\/10.18632\/oncotarget.6691","journal-title":"Oncotarget"},{"issue":"2","key":"1873_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000439594","volume":"2","author":"A Batra","year":"2015","unstructured":"Batra A, Kashyap S, Singh L, Bakhshi S (2015) Sirtuin1 expression and correlation with histopathological features in retinoblastoma. Ocul Oncol Pathol 2(2):86\u201390. https:\/\/doi.org\/10.1159\/000439594","journal-title":"Ocul Oncol Pathol"},{"issue":"1","key":"1873_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","volume":"15","author":"JV Bokhman","year":"1983","unstructured":"Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10\u201317. https:\/\/doi.org\/10.1016\/0090-8258(83)90111-7","journal-title":"Gynecol Oncol"},{"issue":"5666","key":"1873_CR7","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1126\/science.1094637","volume":"303","author":"A Brunet","year":"2004","unstructured":"Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303(5666):2011\u20132015. https:\/\/doi.org\/10.1126\/science.1094637","journal-title":"Science"},{"key":"1873_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.2ru1118-422r","author":"S Chadha","year":"2019","unstructured":"Chadha S, Wang L, Hancock WW, Beier UH (2019) Sirtuin-1 in immunotherapy: a Janus-headed target. J Leukoc Biol. https:\/\/doi.org\/10.1002\/jlb.2ru1118-422r","journal-title":"J Leukoc Biol"},{"issue":"37","key":"1873_CR9","doi-asserted-by":"publisher","first-page":"62537","DOI":"10.18632\/oncotarget.19244","volume":"8","author":"Y Chen","year":"2017","unstructured":"Chen Y, Wang T, Wang W, Hu J, Li R, He S, Yang J (2017) Prognostic and clinicopathological significance of SIRT1 expression in NSCLC: a meta-analysis. Oncotarget 8(37):62537\u201362544. https:\/\/doi.org\/10.18632\/oncotarget.19244","journal-title":"Oncotarget"},{"key":"1873_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092743","author":"U De","year":"2018","unstructured":"De U, Son JY, Sachan R, Park YJ, Kang D, Yoon K et al (2018) A new synthetic histone deacetylase inhibitor, MHY2256, induces apoptosis and autophagy cell death in endometrial cancer cells via p53 acetylation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19092743","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1873_CR11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00204-016-1784-x","volume":"91","author":"CM Deus","year":"2017","unstructured":"Deus CM, Serafim TL, Magalh\u00e3es-Novais S, Vila\u00e7a A, Moreira AC, Sard\u00e3o VA et al (2017) Sirtuin 1-dependent resveratrol cytotoxicity and pro-differentiation activity on breast cancer cells. Arch Toxicol 91(3):1261\u20131278. https:\/\/doi.org\/10.1007\/s00204-016-1784-x","journal-title":"Arch Toxicol"},{"key":"1873_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-1-4939-3667-0_12","volume":"1436","author":"AR Gomes","year":"2016","unstructured":"Gomes AR, Yong JS, Kiew KC, Aydin E, Khongkow M, Laohasinnarong S, Lam EW (2016) Sirtuin1 (SIRT1) in the acetylation of downstream target proteins. Methods Mol Biol 1436:169\u2013188. https:\/\/doi.org\/10.1007\/978-1-4939-3667-0_12","journal-title":"Methods Mol Biol"},{"issue":"2","key":"1873_CR13","doi-asserted-by":"publisher","first-page":"e0192881","DOI":"10.1371\/journal.pone.0192881","volume":"13","author":"M Heckl","year":"2018","unstructured":"Heckl M, Schmoeckel E, Hertlein L, Rottmann M, Jeschke U, Mayr D (2018) The ARID1A, p53 and ss-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium. PLoS ONE 13(2):e0192881. https:\/\/doi.org\/10.1371\/journal.pone.0192881","journal-title":"PLoS ONE"},{"key":"1873_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/ncomms1001","volume":"1","author":"D Herranz","year":"2010","unstructured":"Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, Serrano M (2010) Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 1:3. https:\/\/doi.org\/10.1038\/ncomms1001","journal-title":"Nat Commun"},{"issue":"10","key":"1873_CR15","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/PAS.0b013e31816b6478","volume":"32","author":"KY Jang","year":"2008","unstructured":"Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR et al (2008) SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 32(10):1523\u20131531. https:\/\/doi.org\/10.1097\/PAS.0b013e31816b6478","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1873_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/00313020902884451","volume":"41","author":"KY Jang","year":"2009","unstructured":"Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS et al (2009) Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 41(4):366\u2013371. https:\/\/doi.org\/10.1080\/00313020902884451","journal-title":"Pathology"},{"key":"1873_CR17","volume-title":"International Agency for Research on Cancer, World Health Organization WHO classification of tumours of female reproductive organs","author":"RJ Kurman","year":"2014","unstructured":"Kurman RJ, Carcangiu M, Herrington CS, Young RH (2014) International Agency for Research on Cancer, World Health Organization WHO classification of tumours of female reproductive organs. International Agency for Research on Cancer, Lyon"},{"issue":"10","key":"1873_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nrd2665","volume":"7","author":"S Lavu","year":"2008","unstructured":"Lavu S, Boss O, Elliott PJ, Lambert PD (2008) Sirtuins\u2013novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7(10):841\u2013853. https:\/\/doi.org\/10.1038\/nrd2665","journal-title":"Nat Rev Drug Discov"},{"issue":"3\u20134","key":"1873_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1947601912475079","volume":"4","author":"Z Lin","year":"2013","unstructured":"Lin Z, Fang D (2013) The roles of SIRT1 in cancer. Genes Cancer 4(3\u20134):97\u2013104. https:\/\/doi.org\/10.1177\/1947601912475079","journal-title":"Genes Cancer"},{"issue":"10","key":"1873_CR20","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1091\/mbc.e05-01-0033","volume":"16","author":"E Michishita","year":"2005","unstructured":"Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16(10):4623\u20134635. https:\/\/doi.org\/10.1091\/mbc.e05-01-0033","journal-title":"Mol Biol Cell"},{"issue":"6","key":"1873_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/pai.0000000000000316","volume":"25","author":"DH Mvunta","year":"2017","unstructured":"Mvunta DH, Miyamoto T, Asaka R, Yamada Y, Ando H, Higuchi S et al (2017) Overexpression of SIRT1 is associated with poor outcomes in patients with ovarian carcinoma. Appl Immunohistochem Mol Morphol 25(6):415\u2013421. https:\/\/doi.org\/10.1097\/pai.0000000000000316","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"1873_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.prp.2013.03.011","volume":"209","author":"SJ Noh","year":"2013","unstructured":"Noh SJ, Baek HA, Park HS, Jang KY, Moon WS, Kang MJ et al (2013a) Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer. Pathol Res Pract 209(6):365\u2013370. https:\/\/doi.org\/10.1016\/j.prp.2013.03.011","journal-title":"Pathol Res Pract"},{"issue":"6","key":"1873_CR23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/PAT.0b013e3283652c7a","volume":"45","author":"SJ Noh","year":"2013","unstructured":"Noh SJ, Kang MJ, Kim KM, Bae JS, Park HS, Moon WS et al (2013b) Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients. Pathology 45(6):574\u2013580. https:\/\/doi.org\/10.1097\/PAT.0b013e3283652c7a","journal-title":"Pathology"},{"issue":"6","key":"1873_CR24","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2174\/1389450111314060005","volume":"14","author":"MR Pinzone","year":"2013","unstructured":"Pinzone MR, Cacopardo B, Condorelli F, Di Rosa M, Nunnari G (2013) Sirtuin-1 and HIV-1: an overview. Curr Drug Targets 14(6):648\u2013652","journal-title":"Curr Drug Targets"},{"key":"1873_CR25","unstructured":"Robert Koch-Institut (Hrsg.) (2010) Verbreitung von Krebserkrankungen in Deutschland. Entwicklung der Pr\u00e4valenzen zwischen 1990 und 2010. Beitr\u00e4ge zur Gesundheitsberichterstattung des Bundes. RKI, Berlin"},{"issue":"1","key":"1873_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1873_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/mco.2014.427","volume":"3","author":"M Teramae","year":"2015","unstructured":"Teramae M, Fukuda T, Wada T, Kawanishi M, Imai K, Yamauchi M et al (2015) Sirtuin1 expression predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer. Mol Clin Oncol 3(1):73\u201378. https:\/\/doi.org\/10.3892\/mco.2014.427","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"1873_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.molcel.2004.08.031","volume":"16","author":"A Vaquero","year":"2004","unstructured":"Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D (2004) Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 16(1):93\u2013105. https:\/\/doi.org\/10.1016\/j.molcel.2004.08.031","journal-title":"Mol Cell"},{"issue":"2","key":"1873_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0092-8674(01)00527-X","volume":"107","author":"H Vaziri","year":"2001","unstructured":"Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107(2):149\u2013159","journal-title":"Cell"},{"issue":"10","key":"1873_CR30","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.7754\/Clin.Lab.2016.160317","volume":"62","author":"J Wang","year":"2016","unstructured":"Wang J, Wang C (2016) Prognostic and predictive role of sirtuin1 expression in lung adenocarcinoma. Clin Lab 62(10):1989\u20131994. https:\/\/doi.org\/10.7754\/Clin.Lab.2016.160317","journal-title":"Clin Lab"},{"issue":"16","key":"1873_CR31","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1008433","journal-title":"N Engl J Med"},{"issue":"1","key":"1873_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.cd-12-0361","volume":"3","author":"JN Wu","year":"2013","unstructured":"Wu JN, Roberts CW (2013) ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov 3(1):35\u201343. https:\/\/doi.org\/10.1158\/2159-8290.cd-12-0361","journal-title":"Cancer Discov"},{"issue":"6","key":"1873_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.14715\/cmb\/2018.64.6.7","volume":"64","author":"X Xia","year":"2018","unstructured":"Xia X, Zhou X (2018) Knockdown of SIRT1 inhibits proliferation and promotes apoptosis of paclitaxel-resistant human cervical cancer cells. Cell Mol Biol (Noisy-le-grand) 64(6):36\u201341","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"4","key":"1873_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/CEJ.0b013e328329d830","volume":"18","author":"A Zucchetto","year":"2009","unstructured":"Zucchetto A, Serraino D, Polesel J, Negri E, De Paoli A, Dal Maso L et al (2009) Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev 18(4):316\u2013321","journal-title":"Eur J Cancer Prev"}],"container-title":["Histochemistry and Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00418-020-01873-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00418-020-01873-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00418-020-01873-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T23:41:22Z","timestamp":1620517282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00418-020-01873-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,9]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1873"],"URL":"https:\/\/doi.org\/10.1007\/s00418-020-01873-x","relation":{},"ISSN":["0948-6143","1432-119X"],"issn-type":[{"value":"0948-6143","type":"print"},{"value":"1432-119X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,9]]},"assertion":[{"value":"11 March 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T.M. Kolben is employed at Roche and holds stock of Roche. A. Burges has received advisory board and honoraria from AstraZeneca, Roche, and Tesaro. F. Trillsch declares Research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Medac, PharmaMar, Roche, Tesaro. S. Mahner has received Research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Medac, MSD, Novartis, Olympus, PharmaMar, Roche, Sensor Kinesis, Teva, Tesaro\u00b8 T. Kolben is relative employed at Roche and holds stock of Roche. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the local ethics committee of the LMU Munich (reference number 19-249) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. As all data were anonymized, informed consent was not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}